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Enhanced bronchial responsiveness during and following lower respiratory tract infections is a
major clinical problem, but its pathogenesis is poorly understood. Brain-derived neurotrophic
factor (BDNF), which can be released by platelets and leukocytes, has been identified as a
mediator of bronchial hyperresponsiveness. It is unknown whether the release of BDNF is
altered during lower respiratory tract infections of the adult. In this clinical pilot study, 16
patients (35–80 years old) with the diagnosis of an acute bacterial lower respiratory tract
infection and elevated serum concentrations of c-reactive protein (4100mg/ml) and
procalcitonin (40.1ng/ml) were examined on admission to the hospital and 1 week after
antibiotic treatment. Sixteen age- and sex-matched controls were examined in the same time
period. BDNF concentrations in serum and platelets, but not in plasma, were markedly reduced
in patients on the day of admission (median o25% of the controls). Analysis of the platelet
marker serotonin (5-HT) suggested that the decrease of platelet BDNF is part of a non-specific
release of platelet-derived mediators in this condition. Clinical improvement was accompanied
by a restoration of serum and platelet BDNF concentrations which returned to control levels
after 1 week of treatment. Cell culture experiments revealed that bacterial lipopolysaccharide
(LPS) enhanced the release of BDNF by peripheral blood mononuclear cells of the patients at
both time points. In conclusion, these data suggest that lower respiratory tract infections might
be associated with an augmented release of BDNF by platelets and mononuclear cells.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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M. Lommatzsch et al.1494Introduction blood chemistry (including c-reactive protein, CRP, andAn exaggerated responsiveness of the airways during and
following lower respiratory tract infections (LRTI) is a major
clinical problem, particularly in patients with pre-existing
airway diseases.1 However, its pathogenesis is unclear and
specific treatment options are not available. Although there
is evidence that an increased reactivity of airway nerves
contributes to bronchial hyperresponsiveness in this condi-
tion, the precise mechanisms are poorly understood.2,3
Brain-derived neurotrophic factor (BDNF), a key regulator of
neuronal plasticity and excitability,4,5 has recently been
identified as a mediator of enhanced neuronal reactivity in
the airways.6,7 BDNF is constitutively expressed in the
airway epithelium and smooth muscle.8,9 Enhanced BDNF
secretion by epithelia and leukocytes10,11 contributes to
bronchial hyperresponsiveness in models of asthma.12 There
is increasing evidence that infections are associated with
BDNF overexpression.13–15 Therefore, BDNF has been sug-
gested as a potential trigger of enhanced bronchial respon-
siveness in infected human airways.14
Large amounts of BDNF are stored in human platelets.16
The difference between high BDNF concentrations in serum
and very low BDNF concentrations in plasma17 is attributable
to a BDNF release from platelets during the clotting
process.16 Therefore, this difference between serum and
plasma BDNF levels, corrected for the individual platelet
count, represents an estimate for the individual amount of
platelet BDNF.17,18 BDNF is not produced by platelets or its
precursors but actively taken up by platelets.16 In addition,
the wide range of platelet BDNF concentrations is not
attributable to the individual age, body weight or
height.16,17 Recent studies demonstrating that platelet
BDNF can change rapidly19,20 confirmed the concept that
platelets represent a highly dynamic repository of BDNF in
human peripheral blood.
Since platelets release their mediators at the sites of
inflammation,21 it is likely that platelet-derived BDNF
impacts on neuronal function in inflamed tissues. This
hypothesis is supported by the finding that elevated
concentrations of BDNF in platelets correlate with bronchial
hyperresponsiveness in patients with asthma.18 Although
respiratory tract infections of the adult are associated with
an exaggerated responsiveness of the airways, there is
currently no information on platelet-derived or leukocyte-
derived BDNF in this condition. This clinical pilot study,
therefore, aimed to investigate BDNF concentrations in
platelets and plasma, and the secretion of BDNF by mono-
nuclear cells during acute LRTI of the adult.
Methods
Study design
This study was conducted at the University Hospital of
Rostock (Germany). Patients who presented with cough,
dyspnoea, or both (as the main symptom) at the medical
emergency department were assessed for eligibility. The
assessment at the emergency department included com-
plete history, physical examination, measurement of body
temperature, blood sampling for hematological analysis andprocalcitonin, PCT), capillary blood gases, and conventional
chest radiography. Additional diagnostic procedures and the
choice of the antibiotic regimen were left to the attending
physician. The study was approved by the local ethics
committee. All participants gave their written informed
consent. Patients were examined on the day of admission to
the hospital (‘‘day 1’’), and 1 week after antibiotic
treatment (‘‘day 8’’). Inclusion criteria for the study were
as follows: (1) onset of dyspnoea and/or cough within the
last 7 days prior to admission, (2) radiological and clinical
signs suggesting pneumonia, or purulent sputum in patients
with chronic obstructive pulmonary disease, (3) CRP levels
4100 mg/ml and PCT levels 40.10 ng/ml serum. Exclusion
criteria were: (1) unstable clinical conditions requiring
intubation and/or transfer to the intensive care unit, (2)
other acute inflammatory diseases, (3) malignant diseases,
(4) haemodialysis therapy, or (5) treatment with immuno-
suppressive drugs. In the same time period, age- and sex-
matched volunteers were recruited as controls. Inclusion
criteria for the controls were: (1) no signs of an acute
infection, (2) no history of chronic inflammatory diseases,
(3) c-reactive protein (CRP) concentrations o5 mg/ml and
procalcitonin (PCT) levels o0.10 ng/ml serum. Exclusion
criteria for controls were: (1) malignant diseases, (2)
haemodialysis therapy, or (3) treatment with immunosup-
pressive drugs.Blood parameters and cell culture
Blood was drawn from the cubital vein, into heparinised
(plasma), additive-free (serum) and EDTA-containing (for
cell separation and blood cell counts) containers, and placed
on ice immediately. Heparinised (plasma) and additive-free
(serum) containers were placed on ice for 60min. After-
wards, serum and plasma samples were obtained by
centrifugation for 15min (2000g, 4 1C), and stored at
80 1C until measured.17 Blood cell counts and serotonin
(5-HT) were measured as described.17 BDNF concentrations
in serum, plasma and cell culture supernatants were
measured using a commercial enzyme-linked immunosor-
bent assay (ELISA) following the manufacturers instructions
(DuoSet BDNF ELISA, R&D Systems, Minneapolis, USA).
All BDNF measurements were performed in duplicate.
Serum samples were diluted 1:50, plasma samples were
diluted 1:2 in phosphate buffered saline (PBS) for BDNF
measurement. The detection limit was 4 pg BDNF/ml.
Platelet BDNF content was calculated by subtracting plasma
BDNF from serum BDNF, and dividing the result by the
platelet count, as described.17,18 Platelet 5-HT content
was calculated accordingly. C-reactive protein (detec-
tion limit: 1 mg/ml serum) was measured using Synchron
LX 20 (Beckman Coulter, Krefeld, Germany), procalcitonin
(detection limit: 0.06 ng/ml serum) was measured with
the Kryptor PCT automated assay (Brahms, Hennigsdorf,
Germany).22 Monocyte-enriched PBMC were isolated for
cell culture experiments as described,18 and 2 106 cells/ml
cultured in RPMI 1640 with 10% fetal calf serum, 100U/ml
penicillin, 100 mg/ml streptomycin for 24 h. PBMC were
stimulated with 50 ng/ml tumor necrosis factor alpha
(TNF-alpha) or 100ng/ml bacterial lipopolysaccharide (LPS)
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aliquoted and stored at 80 1C until measured.
Statistical analysis
Data were analysed using SPSS (SPSS Inc., Chicago, IL, USA).
Most parameters were non-normally distributed. Therefore,
the Mann–Whitney U test was chosen for the comparison of
patients and controls. The Wilcoxon signed rank test was
used for comparisons of patients at the two time points, and
for the comparison of cell cultures with and without
stimulation. Correlations were calculated using Spearman’s
correlation coefficient. p-values o0.05 were regarded as
significant.
Results
Characteristics of the participants
Twenty-four patients with the clinical diagnosis of an acute
bacterial LRTI were included in the study. Eight patients had
to be excluded subsequently, due to concurrent cholecystitis
(1 patient), newly diagnosed carcinoma (4 patients), death
(1 patient), surgical treatment for empyema (1 patient),
and a history of recurrent pneumonia in the middle lobe
suggesting chronic recurrent infection (1 patient), resulting
in a final cohort of 16 patients (Table 1). The majority (12
out of 16 patients) were smokers, with a median smoking
history of 35 (range: 10–100) pack years (Table 1). Vital signs
and the blood gas analysis on admission (day 1) are displayed
in Table 2. All patients suffered from hypoxemia
(PaO2o70mmHg) on admission, whereas only two patients
displayed hypercapnia (PaCO2445mmHg). None of the
patients displayed acidosis (pHo7.35) on admission. Tachy-Table 1 Patient characteristics.
Patient no. Gender Age Pack years
1 Male 64 40
2 Female 35 0
3 Male 75 30
4 Female 80 40
5 Male 39 20
6 Male 52 40
7 Female 43 20
8 Female 80 0
9 Male 55 30
10 Male 68 30
11 Male 75 45
12 Male 80 100
13 Male 64 40
14 Male 65 0
15 Male 65 10
16 Male 78 0
The table displays the age and gender of the patients, the smoking
exacerbation of chronic obstructive pulmonary disease), the antibi
hospital stay.cardia (4100 beats/min) was present in 9 out of 16 patients
(Table 2). Sixteen age- and sex-matched controls were
recruited in the same time period. None of the controls
reported any acute or chronic disease, and none of the
controls was on regular medication. The majority of the
controls (11 out of 16 controls) were smokers, with a median
smoking history of 20 (range: 10–50) pack years.
After admission, patients received standard medical care
(oxygen delivery and inhalation therapy) and were treated
with antibiotics for at least 7 days. One patient who initially
received cefuroxime was put on vancomycin (on day 3) due
to methicillin-resistant staphylococcus aureus (MRSA) in a
sputum culture (Table 1). Sputum cultures from 4 patients
yielded positive results in 2 cases, and blood cultures from 5
patients gave 2 positive results. All 16 patients showed a
significant improvement in clinical and laboratory para-
meters after 1 week of treatment, and were discharged
after a median hospital stay of 9.5 days (Table 1). Patients
displayed high concentrations of CRP and PCT, and elevated
leukocyte counts on admission (day 1). All parameters
decreased significantly after 1 week of antibiotic treatment
(day 8), but remained significantly elevated compared to
the controls (Table 3). Platelet counts were indistinguish-
able between patients on day 1 and controls, but increased
significantly after 1 week of treatment (Table 3).BDNF and 5-HT concentrations in serum, platelets
and plasma
Compared to the control group, serum BDNF (median: 24% of
the controls) and 5-HT concentrations (median: 21% of the
controls) were significantly lower in patients on day 1. This
difference was even more pronounced when evaluating
platelet BDNF (median: 23% of the controls) and 5-HT levelsDiagnosis Antibiotic
treatment
Hospital stay
(days)
Pneumonia Cefuroxime 8
Pneumonia Sultamicillin 8
Pneumonia Cefuroxime 10
AECOPD Sultamicillin 10
Pneumonia Moxifloxacin 10
Pneumonia Levofloxacin 16
Pneumonia Moxifloxacin 14
Pneumonia Cefuroxime 9
AECOPD Cefuroxime/
vancomycin
17
AECOPD Ceftazidime 12
AECOPD Sultamicillin 8
Pneumonia Sultamicillin 8
Pneumonia Levofloxacin 11
Pneumonia Moxifloxacin 8
Pneumonia Levofloxacin 8
Pneumonia Cefuroxime 9
history (in pack years), the clinical diagnosis (AECOPD: acute
otic treatment during the study period, and the length of the
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Table 2 Vital signs and blood gas analysis on admission.
Median Minimum Maximum
Temperature (1C) 38.0 36.7 40.2
Heart rate (bpm) 108 76 127
Systolic BP (mmHg) 128 96 174
Diastolic BP (mmHg) 70 49 100
pH 7.47 7.41 7.60
PaO2 (mmHg) 52.6 42.9 64.7
PaCO2 (mmHg) 34.6 27.8 57.9
The table displays the body temperature, heart rate (bpm: beats per minute), blood pressure (BP), and blood gases (while breathing
ambient air) of the 16 patients on admission (day 1).
Table 3 Cells and inflammatory markers.
Controls Patients on day 1 Patients on day 8
Platelets (106/ml blood) 231 (143–310) 231 (111–491) 295 (209–594)*
Leukocytes (106/ml blood) 5.9 (3.3–7.9) 13.7 (9.2–30.0)* 8.6 (4.5–14.6)*
CRP (mg/ml serum) o1 201 (110–493)* 50 (12–262)*
PCT (ng/ml serum) 0.07 (0.06–0.10) 0.29 (0.13–14.40)* 0.15 (0.06–0.73)*
The table displays the median (range) of platelet and leukocyte counts in peripheral blood as well serum concentrations of c-reactive
protein (CRP) and procalcitonin (PCT), of the controls (n ¼ 16) and of the patients (n ¼ 16) at both time points. Significant differences
compared to the control group (po0.05) are marked with an asterisk.
M. Lommatzsch et al.1496(median: 10% of the controls). In contrast, plasma concen-
trations of BDNF and 5-HT did not differ between controls
and patients on day 1 (Fig. 1). After 1 week of treatment,
serum and platelet BDNF concentrations were significantly
increased and no longer different to the concentrations
measured in controls. Although there was a significant
increase of platelet 5-HT levels after 1 week of treatment,
serum and platelet 5-HT concentrations were still signifi-
cantly lower compared to the control group at this time
point (Fig. 1).
Association with clinical parameters
Vital signs (temperature, heart rate, blood pressure) were
not significantly correlated with BDNF levels in serum,
platelets or plasma on admission (data not shown). There
were non-significant trends (p40.05) to negative correla-
tions between platelet BDNF levels and CRP (r ¼ 0.29) or
PCT levels (r ¼ 0.13) on admission. PaCO2 values and PaO2
values did not correlate significantly with BDNF concentra-
tions in peripheral blood. In contrast, pH values on
admission were negatively correlated with BDNF concentra-
tions in serum (r ¼ 0.60, po0.05), platelets (r ¼ 0.53,
po0.05) and plasma (r ¼ 0.74, po0.01).
BDNF secretion by peripheral blood mononuclear
cells
There were no significant differences in BDNF concentra-
tions in cell culture supernatants of unstimulated PBMC
between controls (median: 13.1 pg/ml), patients on day 1(median: 14.6 pg/ml) and patients on day 8 (median:
20.6 pg/ml). Stimulation with TNF-alpha or LPS increased
BDNF concentrations significantly (Fig. 2). There were no
significant differences in the TNF-alpha- or LPS-induced
increase in BDNF concentrations between controls and
patients at both time points (Fig. 2).Discussion
Platelets play a critical role in inflammatory processes of the
lung. They release potent mediators into the local micro-
environment, mainly because of intravascular activation,
but also because of transmigration into inflamed parench-
yma.21,23,24 This pilot study is the first to demonstrate that
platelet BDNF is markedly reduced in patients with an acute
LRTI. In addition, we show that platelet BDNF concentra-
tions recover after only 1 week of successful treatment. It
cannot be completely excluded that the medication of the
patients could have interfered with the BDNF release or with
the BDNF measurements. However, since the medication
was almost identical on days 1 and 8 of the study it appears
highly unlikely that the medication accounted for the
differences in BDNF platelet concentrations. Therefore,
the changes of BDNF platelet concentrations appear to be
specifically attributable to the LRTI. The reduction of
platelet BDNF during the acute LRTI could either be due to
a decreased uptake or an increased release of BDNF by
platelets.16 Previous studies suggested an enhanced release
of platelet-derived mediators during acute infections.25,26 In
addition, there is evidence indicating BDNF overexpression
in infected organs.13–15 Therefore, we hypothesised that low
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Figure 1 BDNF and 5-HTconcentrations in serum, plasma and platelets. Shown are the concentrations of BDNF (upper panel) and 5-
HT (lower panel) in serum, plasma and platelets, of the following groups: control group (C, white boxes), patients on the day of
admission to the hospital (d1, dark grey boxes), and the same patients after 1 week of antibiotic treatment (d8, light grey boxes).
Asterisks mark significant differences (po0.05) between groups or time points; ns denotes not significant (p40.05). Boxplot graphs
display the median (line within the box), interquartile range (edges of the box) and the range of all values less distant than 1.5
interquartile ranges from the upper or lower quartile (vertical lines).
BDNF in lower respiratory tract infections 1497platelet BDNF concentrations are due to an enhanced
release, rather than a decreased uptake of BDNF in this
condition.
To test this, we examined the platelet marker serotonin
(5-HT), which is known to be released from human platelets
during bacterial infections.25,26 The decreases of 5-HT and
BDNF platelet concentrations during the acute LRTI (day 1)
were strikingly similar. Thus, it is likely that the reduction of
platelet BDNF is indeed reflecting an enhanced release of
BDNF in this condition. Of note, BDNF and 5-HTare stored in
different granules of the platelet. While 5-HT is stored in
platelet dense-core granules, BDNF is most likely localised in
platelet alpha-granules.17–20 Therefore, the parallel de-
crease of BDNF and 5-HT platelet concentrations suggests a
rather non-specific release of platelet mediators during an
acute LRTI. Notably, platelet BDNF and 5-HT significantly
increased after 1 week of treatment. This finding suggests
that platelet BDNF and 5-HT stores recover after clinical
improvement. However, it appears that there are differ-
ences in the time course. After 1 week of treatment,
platelet BDNF returned to control levels, whereas platelet
5-HT was still markedly decreased. This could be attribu-
table to the storage of BDNF and 5-HT in different platelet
granules, which differ considerably in physiology andfunction.27,28 In contrast to platelet concentrations, plasma
levels of BDNF and 5-HT remained unaltered during the
acute LRTI. In the literature, a very short plasma half-life of
BDNF (o1min)29 and 5-HT (o2min)30 has been reported.
Therefore, our observations would be compatible with a
rapid clearance of platelet-derived BDNF and 5-HT from the
circulation in this condition.
However, the actual site of the BDNF release by platelets
is yet unclear. Platelets may release BDNF within the
pulmonary circulation. This would result in low BDNF levels
in circulating platelets, as observed in our study. A rapid
clearance of platelet-derived BDNF from the plasma (either
by enzymatic degradation or by yet unknown transport
mechanisms into the perfused tissue) would explain the
unchanged BDNF plasma levels during the LRTI (see above).
However, platelets have also been postulated to transmi-
grate into the inflamed lung parenchyma, either alone (by
active diapedesis) or in conjunction with leukocytes (in
platelet-leukocyte aggregates).21,23,24 In this scenario, BDNF
would be directly released from transmigrating platelets
into the lung parenchyma. The pulmonary sequestration of
mature platelets and the infection-related thrombopoiesis
in the bone marrow would be an alternative explanation for
the low platelet BDNF concentrations measured: since BDNF
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Figure 2 Release of BDNF by cultured mononuclear cells. Monocyte-enriched PBMC were cultured and stimulated with TNF-alpha
(left panel) or LPS (right panel) for 24 h. Boxplots display BDNF concentrations in supernatants after stimulation, in percent of the
corresponding medium control, of the following groups: control group (C, white boxes), patients on the day of admission to the
hospital (d1, dark grey boxes), and the same patients after 1 week of antibiotic treatment (d8, light grey boxes). Significant
differences (po0.05) compared to the corresponding medium control are marked with asterisks. The BDNF release did not
significantly differ between the groups or time points (ns denotes not significant). Boxplot details are described in Fig. 1.
M. Lommatzsch et al.1498is not produced in megakaryocytes but actively taken up by
circulating platelets,16 an enhanced percentage of newly
released platelets should result in low median platelet BDNF
levels.
The underlying cause of the BDNF release by platelets is
speculative. Due to the non-specific character of the
release, immunological mechanisms leading to an activation
and degranulation of platelets appear to be likely.25 Indeed,
the release of BDNF by platelets has been shown to be
stimulated by a variety of agonists which play a role in
inflammatory processes.16 An altered acid-base balance
might influence this BDNF release since we found an
association between pH values and platelet BDNF concen-
trations. On the other hand, a contribution of LRTI-
associated mood disturbances to reduced platelet BDNF
concentrations appears unlikely. Mood disorders are char-
acterised by a specific decrease in BDNF production. A non-
specific release of BDNF and other mediators by platelets
does not comply with current concepts of mood disorders.31
The amount of BDNF secreted by monocytes, which
represent the major source of BDNF among leukocytes,32 is
lower than the amount of BDNF secreted by platelets.
Platelets in 1ml of human blood can release more than 10 ng
of BDNF,16 whereas monocytes in 1ml of human blood
release less than 1 ng of BDNF.32 Nevertheless, monocytes
might contribute to a sustained local release of BDNF. We,
therefore, measured BDNF secretion of monocyte-enriched
PBMC of patients and controls. We found no differences in
the releasibility of BDNF from mononuclear cells between
patients and controls. However, bacterial LPS significantly
enhanced the release of BDNF, which was consistent with
previous data from an animal model.33 Therefore, LPS mightaugment the secretion of BDNF by infiltrating mononuclear
cells in infected airways.
In conclusion, our data suggest that lower respiratory
tract infections might be associated with an augmented
release of BDNF by platelets, as part of a general release
of platelet-derived mediators in this condition. Mono-
nuclear cells stimulated with bacterial LPS could further
enhance local BDNF concentrations. Because BDNF causes
neuronal hyperexcitability, we hypothesise that an in-
creased BDNF secretion by platelets and leukocytes might
contribute to an exaggerated responsiveness of the airways
in respiratory tract infections. Further clinical and experi-
mental studies which include bronchoalveolar lavage, lung
biopsies and lung function tests are needed to test this
hypothesis.References
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